You just read:

European Hematology Association: Overall Survival Benefit of Obinutuzumab Over Rituximab When Combined With Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Comorbidities

News provided by

European Hematology Association

15 Jun, 2018, 07:30 BST